BDTX (Black Diamond Therapeutics) ROE % Adjusted to Book Value: -28.54% (As of Mar. 2026)


BDTX Black Diamond Therapeutics Inc BDTX
37 GF Score
Price $1.71
! 2 Warning Signs
View Full Analysis

What is Black Diamond Therapeutics ROE % Adjusted to Book Value?

Black Diamond Therapeutics BDTX +0.59% 37 ROE % Adjusted to Book Value is -28.54% as of Mar. 2026. GuruFocus rates BDTX with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Black Diamond Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -33.39%. Black Diamond Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 1.17. Black Diamond Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -28.54%.

Black Diamond Therapeutics ROE % Adjusted to Book Value Related Terms

Black Diamond Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Black Diamond Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Black Diamond Therapeutics ROE % Adjusted to Book Value Chart

Black Diamond Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only -50.37 -102.67 -57.21 -47.72 18.45

Black Diamond Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 324.55 -29.08 -15.36 -40.91 -28.54

BDTX vs CGTX, PMN, PTHS: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Black Diamond Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Diamond Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's ROE % Adjusted to Book Value falls into.


BDTX
37GF Score
Black Diamond Therapeutics Inc BDTX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Black Diamond Therapeutics ROE % Adjusted to Book Value Calculation

Black Diamond Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=22.88% / 1.24
=18.45%

Black Diamond Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-33.39% / 1.17
=-28.54%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -28.54% mean?
Black Diamond Therapeutics (BDTX) has a ROE % Adjusted to Book Value of -28.54% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Black Diamond Therapeutics and its competitors.
Is Black Diamond Therapeutics' ROE % Adjusted to Book Value too high?
Black Diamond Therapeutics' current ROE % Adjusted to Book Value is -28.54%. Overall, Black Diamond Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Black Diamond Therapeutics' ROE % Adjusted to Book Value compare to CGTX and PMN?
Black Diamond Therapeutics' ROE % Adjusted to Book Value of -28.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Black Diamond Therapeutics and its competitors. Black Diamond Therapeutics's current ROE % Adjusted to Book Value is -28.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Black Diamond Therapeutics stock overvalued right now?
Black Diamond Therapeutics (BDTX) has a current ROE % Adjusted to Book Value of -28.54%. The current ROE % Adjusted to Book Value is -28.54%. Black Diamond Therapeutics' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Black Diamond Therapeutics (BDTX), the current ROE % Adjusted to Book Value is -28.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Black Diamond Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
37GF Score

Get the complete analysis for BDTX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price